Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group

dc.contributor.authorid0000-0001-8340-2678
dc.contributor.coauthorKaplan, Muhammet Ali
dc.contributor.coauthorSendur, Mehmet Ali Nahit
dc.contributor.coauthorCangir, Ayten Kayi
dc.contributor.coauthorGoker, Erdem
dc.contributor.coauthorKilickap, Saadettin
dc.contributor.coauthorOyan, Basak
dc.contributor.coauthorOz, Aysim Buge
dc.contributor.coauthorOzdemir, Feyyaz
dc.contributor.coauthorOzyigit, Gokhan
dc.contributor.departmentN/A
dc.contributor.kuauthorFırat, Pınar Arıkan
dc.contributor.kuprofileFaculty Member
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.yokid207545
dc.date.accessioned2025-01-19T10:30:58Z
dc.date.issued2023
dc.description.abstractPleural mesothelioma (PM) is a cancer of the pleural surface, which is aggressive and may be rapidly fa-tal. PM is a rare cancer worldwide, but is a relatively common disease in Turkey. Asbestos exposure is the main risk factor and the most common underlying cause of the disease. There have been significant im-provements in diagnoses and treatments of many malignancies; however, there are still therapeutic chal-lenges in PM. In this review, we aimed to increase the awareness of health care professionals, oncolo-gists, and pulmonologists by underlining the unmet needs of patients with PM and by emphasizing the need for a multidisciplinary treatment and management of PM. After reviewing the general information about PM, we further discuss the treatment options for patients with PM using immunotherapy and offer evidence for improvements in the clinical outcomes of these patients because of these newer treatment modalities.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue6
dc.description.openaccesshybrid
dc.description.publisherscopeInternational
dc.description.sponsorsThe authors thank Safak Duelger (BSc) from Omega CRO, Ankara, Turkey for professional medical writing and assistance, with funding from Bristol Myers Squibb, Istanbul, Turkey.
dc.description.volume47
dc.identifier.doi10.1016/j.currproblcancer.2023.101017
dc.identifier.eissn1535-6345
dc.identifier.issn0147-0272
dc.identifier.quartileQ3
dc.identifier.scopus2-s2.0-85173875640
dc.identifier.urihttps://doi.org/10.1016/j.currproblcancer.2023.101017
dc.identifier.urihttps://hdl.handle.net/20.500.14288/26159
dc.identifier.wos1125100500001
dc.keywordsBiomarker
dc.keywordsCancer
dc.keywordsChemotherapy
dc.keywordsImmune checkpoint inhibitor
dc.keywordsImmunotherapy
dc.keywordsPleural mesothelioma
dc.languageen
dc.publisherMosby-Elsevier
dc.relation.grantnoBristol Myers Squibb, Istanbul, Turkey
dc.sourceCurrent Problems in Cancer
dc.subjectOncology
dc.titleEstablished and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group
dc.typeJournal Article

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
IR05229.pdf
Size:
491.5 KB
Format:
Adobe Portable Document Format